Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a leading biotechnology company headquartered in the United States, is renowned for its pioneering work in RNA-targeted therapeutics. Founded in 1989, Ionis has established itself as a key player in the pharmaceutical industry, focusing on the development of innovative treatments for a range of serious diseases, including neurological disorders and cardiovascular conditions. With a robust pipeline of drugs, Ionis is particularly noted for its unique antisense technology, which allows for precise modulation of gene expression. This innovative approach has led to significant milestones, including the approval of several groundbreaking therapies. Ionis Pharmaceuticals continues to strengthen its market position through strategic partnerships and a commitment to advancing the field of genetic medicine, making it a notable force in the biopharmaceutical landscape.
DitchCarbon Score
How does Ionis Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ionis Pharmaceuticals's score of 20 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ionis Pharmaceuticals's reported carbon emissions
In 2023, Ionis Pharmaceuticals reported significant carbon emissions, with Scope 2 emissions totalling approximately 2,788,000,000 kg CO2e. This figure reflects a notable focus on purchased electricity, as no Scope 1 emissions data was disclosed for this year. In 2022, the company recorded about 2,456,000,000 kg CO2e in Scope 1 emissions and approximately 1,841,000,000 kg CO2e in Scope 2 emissions, indicating a slight decrease in Scope 1 emissions compared to the previous year. In 2021, Ionis's total emissions from Scope 1 and 2 combined reached about 4,618,000,000 kg CO2e, with Scope 1 emissions at approximately 2,566,000,000 kg CO2e and Scope 2 emissions at around 2,052,000,000 kg CO2e. The emissions intensity for Scope 1 and 2 was reported at about 7,220 kg CO2e per employee in 2021, decreasing to approximately 5,660 kg CO2e per employee in 2022, and further to about 6,110 kg CO2e per employee in 2023. Despite these figures, Ionis Pharmaceuticals has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company continues to navigate its carbon footprint within the pharmaceutical industry, which is increasingly focused on sustainability and climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 2,566,000,000 | 0,000,000,000 | - |
| Scope 2 | 2,052,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ionis Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
